Dexcom Posts Strong Fiscal 2025 Growth on CGM Expansion
Event summary
- Dexcom reported $4.662 billion in full-year revenue for fiscal 2025, up 16% year-over-year.
- GAAP operating income increased by 470 basis points to $911.8 million (19.6% of revenue).
- Launched Dexcom G7 15 Day CGM system in the U.S. and received FDA clearance for Dexcom Smart Basal.
- Expanded coverage under RAMQ, bringing CGM access to eligible adults with type 2 diabetes in Québec.
The big picture
Dexcom's strong fiscal 2025 performance underscores the growing demand for advanced continuous glucose monitoring (CGM) systems. The company’s strategic focus on expanding access to its technology, particularly in international markets and among type 2 diabetes patients, positions it well against competitors like Abbott Diabetes Care. With a robust cash position of $2 billion and clear guidance for fiscal 2026, Dexcom is poised to capitalize on the shift toward personalized diabetes management solutions.
What we're watching
- Market Penetration
- Whether Dexcom can sustain its international revenue growth of 16% amid competitive pressures.
- Regulatory Approvals
- The pace at which new FDA clearances will enable further product differentiation and market share gains.
- Operational Efficiency
- How Dexcom’s expanded production capacity will support its ambitious 11-13% revenue growth guidance for fiscal 2026.
Related topics